FDA Approves Vericiguat for Treatment of Heart Failure

On January 20th it was announced that vericiguat (called VERQUVO commercially) received U.S. FDA approval.

As noted in the press release from Merck, VERQUVO is the first treatment for chronic heart failure approved by the FDA specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics.

The approval for this treatment is based on the results of the Phase 3 VICTORIA trial, which compared vericiguat with a placebo in patients with worsening heart failure and reduced ejection fraction. The study found that vericiguat was superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

More information can be found in the news releases below:

Merck News Release
Bayer News Release
University of Alberta News Release